Deutsch Website, wo Sie Qualität und günstige https://medikamenterezeptfrei2014.com/ Viagra Lieferung weltweit erwerben.

Ein wenig Kopfschmerzen, aber schnell verging der Schmerz. Gefühle, die ich erlebte ein unvergessliches levitra kaufen Ehrlich gesagt nicht wirklich glauben, in der Kraft Viagra. Setzte nach der Anleitung. Das Ergebnis ist natürlich, sich selbst rechtfertigte.

Microsoft word - booklet agami.doc

D R . J O S E F S T E I N E R
K R E B S S T I F T U N G
D R . J O S E F S T E I N E R
K R E B S F O R S C H U N G S P R E I S 2 0 0 7
D R . J O S E F S T E I N E R
K R E B S S T I F T U N G
Der Dr. Josef Steiner Krebsforschungspreis 2007 Herr Agami ist holländisch/israelischer Doppelbürger und arbeitet als ausserordentlicher Professor an der Abteilung für Tumorbiologie am Niederländischen Krebsinstitut. Die Preissumme beträgt CHF 1‘000‘000. D R . J O S E F S T E I N E R
K R E B S S T I F T U N G
DR. JOSEF STEINER
KREBSFORSCHUNGSPREIS 2007
Doktor Josef Steiner, Inhaber der „Dr. Steiner Apotheke und Bahnhofdrogerie“
in Biel, hat bei seinem Tode im Jahre 1983 ein grosses Vermögen hinter-
lassen, welches entsprechend seinem letzten Willen die finanzielle Basis der
Dr. Josef Steiner Krebsstiftung bildet. Ziel der Stiftung ist die Förderung der
Krebsforschung und die Auszeichnung hochverdienter Wissenschafter auf
allen Gebieten der Krebsforschung. Als erster Preisträger konnte 1986 ein
Schweizer, Dr. Peter Cerrutti, geehrt werden. Seither konnten zahlreiche
hervorragende Wissenschafter aus Europa, USA und Australien mit dem Dr.
Josef Steiner Preis ausgezeichnet werden.
Im Bestreben, die Krebsforschung im Sinne des Stifters effizient und
nachhaltig zu fördern, wird seit 1998 ein hervorragendes Forschungsprojekt für
die Periode von drei bis vier Jahren mit einem Betrag von 1’000’000
Schweizerfranken unterstützt. Der Forschungsgruppenleiter oder die
Forschungsgruppenleiterin wird zusätzlich mit einem persönlichen Preis in der
Höhe von 50'000 Schweizerfranken ausgezeichnet.
Die Auswahl des preisgekrönten Projektes erfolgte nach einem mehrstufigen
strengen Auswahlverfahren. Der Dr. Josef Steiner Preis 2007 wurde in
renommierten Wissenschaftszeitschriften ausgeschrieben. Die eingereichten
Projektskizzen wurden vom Stiftungsrat und einer aus Fachvertretern
zusammengesetzten Preiskommission gesichtet und bewertet. Als Kriterien
wurden die wissenschaftliche Qualität und die Originalität der Projektskizzen,
die Qualifikation der Projektverfasser, sowie die Beurteilung der Machbarkeit
der vorgeschlagenen Projekte in Betracht gezogen. Jüngeren Forschern wurde
der Vorzug gegeben. Fünf hervorragende Projektskizzen wurden ausgewählt
und die Verfasser aufgefordert, ein überarbeitetes und detailliertes Projekt
einzureichen. Für jedes Projekt wurden mindestens drei externe Gutachten
eingeholt.
Zusätzlich wurden die fünf Projektverfasser zu einem Symposium eingeladen,
welches am 11. Januar 2007 an der Universität Bern stattgefunden hat.
Anlässlich dieses Symposiums konnten die Forscherinnen und Forscher ihre
Projekte vorstellen. Aus diesem strengen Auswahlverfahren ist Herr Prof. Dr.
Reuven Agami als Sieger hervorgegangen. Der Titel seines Projektes lautet:
Identification and characterization of microRNAs with the capacity to
affect tumor growth and responsiveness to therapy”.

D R . J O S E F S T E I N E R
K R E B S S T I F T U N G
SVIZZENSIS E VICO ALPTHAL ORIUNDUS IBIQUE NATUS PHARMACOPOLAE MUNERE IN MUNICIPIO BIEL PRO VIRILI PARTE TRIBUS VIRIS PERITIS IN CONSILIUM DELECTIS AUCTORIBUS QUI INDAGATOR SAGACISSIMUS MEATUS INTRACELLULARES ILLUSTRAVIT, PER QUOS CELLULAE, QUARUM DNA LAESA EST, PRIUSQUAM IN CANCRI FORMAM MUTARI POSSINT, AUT CONTRA EFFICIANT UT CANCER EXORIATUR, QUI DE NOVIS MEDENDI RATIONIBUS ATQUE VIIS, SINGULA INFRINGI ATQUE EXSTINGUI POSSINT, PRAEMIUM SUPREMA VOLUNTATE MEA PROPOSITUM BERNAE DIE II MENSIS NOVEMBRIS ANNI MMVII D R . J O S E F S T E I N E R
K R E B S S T I F T U N G

Laudatio für Reuven Agami
Reuven Agami, ausserordentlicher Professor am Niederländischen
Krebsforschungsinstitut in Amsterdam erhält den Dr. Josef Steiner
Krebsforschungspreis in Anerkennung seiner Verdienste um die Aufklärung
der Bedeutung der microRNA (miRNA) in der Enstehung von Krebs.
MicroRNA ist eine erst kürzlich entdeckte Genfamilie welche in allen Pflanzen und Tieren, der Mensch eingeschlossen, vorhanden ist. Im mensch-lichen Genom sind tausende dieser miRNAs vorhanden. Im Gegensatz zu den bekannten Genen, kodieren miRNA keine Proteine, sondern regulieren die Funktion der andern, protein-kodierenden Gene. Man geht davon aus, dass alle protein-kodierenden Gene unter der Kontrolle von einem oder mehreren miRNA stehen. Die miRNA interferiert nicht direkt mit den protein-kodierenden Genen, sondern hemmt das unmittelbare Genprodukt, die Messenger-RNA (mRNA), die ihrerseits das Protein kodiert. Die miRNA besitzt zur mRNA komplementäre Nukleodid-Sequenzen, welche es der miRNA erlaubt an diese mRNA zu binden, und somit die Proteinsynthese (Translation) zu hemmen. Die Bindung eines oder mehrer miRNA an eine mRNA führt somit in jedem Fall zu einer Reduktion eines bestimmten Proteins. Man vermutet, dass die zahlreichen miRNAs das für eine Zelle relevante Expressionsmuster der mRNA garantieren und somit für die Aufrechterhaltung der Zellidentität und Zellintegrität verantwortlich sind. Reuven Agami hat entdeckt, dass bestimmte miRNAs fälschlicherweise mRNA unterdrücken können, welche für die Aufrechterhaltung der normalen Zellfunktion unbedingt notwendig sind. Als Folge davon kann die normale Zellidentität gestört werden; die normalen Zellen entarten zu Krebs. Im Gegensatz dazu fand Reuven Agami auch miRNA welche die Expression von bekannten Krebsgenen unterdrücken können. Die bedeutende und weltweit stark beachteten Arbeit von Reuven Agami lassen vermuten, dass er mit Hilfe der miRNA Technik nicht nur bedeutende Fortschritte im Verständnis der molekularen Kontrolle der Krebsentstehung erzielen wird, sondern es besteht auch die begründete Hoffnung, dass miRNA in Zukunft therapeutisch für die Behandlung von Krebsleiden eingesetzt werden können. D R . J O S E F S T E I N E R
K R E B S S T I F T U N G

Laudatio for Reuven Agami

Reuven Agami, Associate Professor at the Netherland Cancer Institute
Amsterdam, is recipient of the Dr. Josef Steiner Award 2007. He receives this
prize in recognition for his development and application of methodologies
based on RNA interference (RNAi), the ability of double-stranded RNA to
efficiently and potently silence any gene in plants, animals and humans, to
systematically define cancer gene functions on a genome-wide scale.
Reuven Agami has spend his entire career working to unravel at the molecular
level how damage of the genetic information, the DNA, makes normal cells
genetically unstable and cancer prone. Already as a graduate student at the
Weizmann Institute of Science, Israel and later as a postdoctoral fellow at the
Netherland Cancer Institute, Amsterdam, he has discovered novel signaling
pathways through which cells initiate their own demise if they experience DNA
damage. He noted that key components of these pathways represent
oncogenes and tumor suppressor genes, providing a mechanism by which
cancer genes promote the accumulation of additional genetic alterations and
tumor cell evolution.
As a principal investigator at the Newtherland Cancer Institute, Reuven Agami
continued to vigorously pursue his work on the DNA damage response
pathway. However, rather than teasing apart the pathway by removing genes
one at a time and looking at the effect, Agami began to develop RNAi-based
methodologies that allow any gene of known sequence to be stably shut down
and the corresponding loss-of-function phenotype studied. This methodology
allowed to systematically silence genes on a genome-wide scale using large
rationally designed libraries targeting many thousands of genes and thus
provided a novel functional genomics approach to the investigation of many
aspects of mammalian cell behaviour, including the DNA damage response
and oncogenic transformation.
RNAi represents an evolutionary conserved cellular defense for controlling the
expression of foreign genes. It is triggered by double-stranded RNA molecules
which silence a gene by elimination of the mRNA corresponding to that gene.
RNAi has already become an important research tool in biology and
biomedicine and is being developed for application in cancer therapy. In 2002,
the journal Science named RNAi ‘the technology of the year’ and in 2006, the
Nobel Prize in Physiology and Medicine was given for the discovery of RNAi.
Work in this field is by no means finished and the application of this technology
is likely to provide unexpected and rich insight into the molecular circuitry
underlying tumor cell evolution. Agami not only set the stage for RNAi-mass
screening of mammalian genes but also applied this new technology to identify
D R . J O S E F S T E I N E R
K R E B S S T I F T U N G

heretofore unknown genes with tumor suppressor function. The impact of
Agami’s work on cancer research has been already superb and led him to
become elected as an EMBO Young Investigator and recipient of the
European Young Investigator Award in 2004. With the Dr. Josef Steiner Prize,
the committee is honoring a highly creative scientist and hopes that this prize
will prove to be a major incentive for further scientific research in the
mechanism and application of RNAi in cancer biology and medicine.
Curriculum Vita Reuven Agami (*1965)
Since September 2005: Associated professor at the Division of Tumor Biology,
The Netherlands Cancer Institute, Amsterdam, The Netherlands.
September 2001 - September 2005: Assistant professor at the Division of Tumor
Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
June 1998 - September 2001: Post-doctoral fellowship at the Division of
Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The
Netherlands.
1993-1999: PhD at the Department of Molecular Genetics, The Weizmann
Institute of Science, Rehovot, Israel. Official date of graduation is 8th June 1999.
1991-1993: MSc at the Department of Membranes and Biophysics, The
Weizmann Institute of Science, Rehovot, Israel.
1987-1991: BSc at Tel-Aviv University, Israel.
I performed my PhD research (Thesis: Cell cycle and apoptosis control induced by the tyrosine kinase c-Abl) within the department of molecular genetics at the Weizmann Institute of Science, Israel. During this period I identified a novel DNA-damage-induced apoptosis pathway that requires the activation of c-Abl kinase and tyrosine phosphorylation of the p53 homologue- p73a. This work was published in the top journal Nature. In 8th June 1999 I recieved my PhD. As a post-doctorate fellow in the group of Prof. Rene Bernards, I initiated my own line of research to identify rapid molecular events that initiate p53-independent DNA damage responses. In July 2000, my work was published in the top journal Cell. In September 2001, I started my own group at the Netherlands Cancer Institute and in September 2005 I became a staff member (associated professor). In these years I developed an D R . J O S E F S T E I N E R
K R E B S S T I F T U N G
RNAi vector system (pSUPER) to stably inhibit gene expression in mammalian cells. This work was published in 2002 in the top journal Science. Since then, the pSUPER system is used worldwide and also in the two research topics in my group. The first research line focuses on the identification of novel DNA damage checkpoint genes that govern cell cycle responses following genotoxic stress. The second research line is the identification of novel tumor suppressor genes using transformation of primary human cells. Here we established a tumor suppressor role for the transcription factor PITX1, work that was published in 2005 in Cell. Recently, we developed research tools to identify cancerous miRNAs. First part of this work was published last year (Voorhoeve et al., 2006) in Cell. The second part is under revision now (le Sage C., Nagel R. and Agami R.,). Honors and Awards Reuven Agami
1999:
EMBO long-term fellowship.
2001: Netherlands Cancer Institute (AVL) award.
2002: Elected fellow of the central for biomedical genetics (CBG).
2004: European Young Investigator Award (EURYI).
2004: VIDI grant.
2004: EMBO young investigator (YIP) award.
2006: Elected young academy member of the Royal Netherlands Academy of
Sciences (DJA-KNAW).
2007: Awarded the Dr. Joseph Steiner Prize, Switzerland - 2007.
2007: Elected EMBO member

Unraveling Functions of microRNAs in Cancer

miRNAs
MicroRNAs (miRNAs) is a newly identified gene family found in all vertebrates, plants,
and invertebrate species. All miRNAs encode short RNA of 22-nucleotides (nt).
Recent estimations suggest the existence of thousands miRNA genes in the human
genome. miRNAs are not translated to protein but rather regulate the expression of
other protein-coding genes. It appears that the majority of protein-coding genes might
be under the regulation of one or more miRNA. Exactly how miRNAs influence
expression of genes is not yet known. It is generally believed that miRNAs regulate
gene expression after message RNA (mRNA, RNA that codes for protein) was
produced from the protein-coding gene. The miRNAs bind to mRNAs, through fully or
partly complementary target sequences. The result of this binding can be either
degradation of the RNA or inhibition of the translation process. Translation is the
process that converts RNA to protein. In general, target mRNAs containing fully
complementary sequences to the miRNA, will be degraded by an RNA-interference
mechanism, whereas targets with partial complementarity will be subjected to
translation inhibition and mRNA decay. In all cases, though, the binding of miRNAs to
mRNAs results in slower production of a particular protein.
D R . J O S E F S T E I N E R
K R E B S S T I F T U N G

Functionally, miRNAs have been suggested to play a role in maintaining the reliability
of mRNA expression patterns. The miRNA and its predicted targets are expressed in
a mutually exclusive manner, ensuring that any illegitimate expression of an mRNA in
a non-relevant tissue is suppressed. In other words, a messenger RNA is expressed
in one cell while a targeting miRNA is expressed in a neighboring cell, taking care that
no leakage expression occurs in the second cell type, thus helping preserving the
different identities of both cell types. In contrast, certain miRNAs have been shown to
elicit a more specific function, which is exerted by the inhibition of a limited number of
targets normally expressed in the same cell. These miRNAs likely to participate in cell
fate decisions during cell growth and differentiation. Importantly, whether a given
miRNA acts to suppress illegitimate expression, or targets directly a subset of genes,
its aberrant expression bares the capacity to cause phenotypic abnormalities in the
cellular level, as well as in the level of the organism. Based on this assumption, we
chose to unravel cancer-related functions of miRNAs using a functional genetic
approach.
Functional genetic approaches identify cancerous miRNAs
Approach 1:
To identify novel functions of miRNAs, we took a functional genetic
approach. We built a vehicle to force the expression of any given miRNA we choose.
Then, we created a large collection of vehicles to allow the forced expression of
almost all known human miRNAs. Additionally, we made a chip to detect and quantify
all these vehicles. We used these tools to identify novel cancer causing miRNAs. The
idea was to use normal human cells that are sensitive to the emergence of oncogenic
mutations. An oncogene is defined as a cancer promoting change in a gene. Once
such a change occurs, normal human cells contain signaling pathways that take care
to prevent abnormal cell growth. We asked: are there any miRNAs that will numb this
defence response and allow the cells to tolerate oncogenic events? – a process that
ultimately leads to cancer. Screening our library revealed a miRNA gene family
named miR-372 that was capable of doing it. Further investigation uncovered the
mechanism (targeting genes) and, most importantly, the oncogenic role of this family
in the development germ cell tumors.
Approach 2: Here we concentrated on protein-coding genes whose role in cancer
was already established. By screening our miRNA library, we experimentally identified
several miRNAs that inhibit the expression of one or some of these cancer genes. The
functional relationship between the cancer gene, the miRNA and cancer is
subsequently unraveled using cell systems and human tumor material. For example
we uncover the role of one miRNA (miR-221) in controlling p27, a tumor suppressor
and cell cycle inhibitor, and unraveled their function to promote cancerous growth of
brain tumors. Most remarkably, inhibition of the miRNA activity stopped proliferation of
cancer cells. We are now examining possibilities to adapt this technology to cancer
treatment in animal models.
Future prospective
I propose to test the idea that some miRNAs may confer resistance to cancer therapy:

miRNAs in Anti-hormonal therapy:
Specific types of tumors, most commonly from
breast and prostate origin, rely on hormones such as estradiol and
D R . J O S E F S T E I N E R
K R E B S S T I F T U N G
dihydrotestosterone to survive and grow. Anti-hormone therapy is a treatment that targets tumors by blocking their ability to respond to the hormones on which they depend. Anti-hormones include, for example, the anti-estrogens tamoxifen and fulvestrant for the treatment of breast cancer, and the anti-androgens flutamide and bicalutamide for the treatment of prostate cancer. However, often the hormone-dependent tumors eventually evolve to become hormone-independent, and thus resistant to anti-hormonal treatments. Since the response of tumor cells to anti-cancer therapy is a consequence of their genetic composition, and because miRNAs are potent regulators of gene expression, we hypothesize that miRNAs may play a role in the regulation of cellular pathways that can lead tumor cells to gain resistance to anti-hormonal therapy. Using the genetic approaches illustrated above we are aiming at the identification of miRNAs whose function can change cell reaction to anti-hormonal therapy. miRNAs in Genotoxic drugs therapy: Chemotherapy is very often used as anti-cancer drugs to treat cancerous cells. Examples are doxorubicin, methotrexat, 5FU and paclitaxel. These drugs kill replicating cells therefore have higher efficiency in eliminating cancer cells. However, quite often resistant-tumors appear following treatment. To uncover whether miRNAs play a role in this phenomenon, we are taking two approaches. First we are comparing the expression of hundreds of miRNAs in resistant versus sensitive tumors. We are using mouse models and human tumor material for that. Second, we perform genetic screens in cellular models to find miRNAs that can confer resistant phenotype to – otherwise – sensitive cells. miRNAs in Metastasis: Metastasis occurs when genetically unstable cancer cells adapt to a tissue microenvironment that is distant from the primary tumor. This process involves both the selection of behavior that are advantageous to cancer cells. We hypothesize that part of this adaptation can either be induced or will require changes in miRNA expression. Using expression analysis as well as functional genetic screens, as explained above, we aim here to identify miRNAs that are potent inducers of metastasis. D R . J O S E F S T E I N E R
K R E B S S T I F T U N G
Dr. Josef Steiner Krebsstiftung, c/o Institut für Physiologie, Universität Bern, Bühlplatz 5,

Source: http://www.steinerstiftung.unibe.ch/pdf/krebsforschungspreis2007.pdf

Banner health system

MEMORANDUM Banner Baywood Medical Center and Banner Heart Hospital Physicians and Nursing Staff Dr. Wendy McLaughlin, MD - Laboratory Medical Director, BBMC Dr. Lucyna Boyle, MD – Laboratory Medical Director, BHH July 18, 2011 SUBJECT: New Laboratory Tests for Determining Patient Response to Plavix or Aspirin On July 21st, 2011, the clinical laboratory will beg

(microsoft word - d\351fience_en_ghb.docx)

Alcohol & Alcoholism Vol. 42, No. 5, p. 506, 2007 doi:10.1093/alcalc/agm058 Advance Access publication 1 August 2007 GAMMA-HYDROXYBUTYRATE (GHB)-DEFICIENCY IN ALCOHOL-DEPENDENCE? 23 rue du Depart—BP 37—7 5014 Paris, France (Received 10 January 2007; first review notified 17 January 2007; in revised form 3 March 2007; accepted 28 March 2007; advance access publication 1 August 2007) J

Copyright © 2010-2014 Health Drug Pdf